
Global CGT Drugs Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global CGT Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for CGT Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for CGT Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the CGT Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for CGT Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the CGT Drugs market include Bluebird Bio, Celgene Corporation, Juno Therapeutics, Kite Pharma, Orchard Therapeutics, Spark Therapeutics, Amgen, Fosun Kite Biotechnology and GSK, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for CGT Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of CGT Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for CGT Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CGT Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global CGT Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for CGT Drugs sales, projected growth trends, production technology, application and end-user industry.
CGT Drugs Segment by Company
Bluebird Bio
Celgene Corporation
Juno Therapeutics
Kite Pharma
Orchard Therapeutics
Spark Therapeutics
Amgen
Fosun Kite Biotechnology
GSK
Novartis
SiBiono
Sunway Biotech
Janssen Biotech
Sequoia
CGT Drugs Segment by Type
CAR-T Therapy
Viral Vector Therapy
Stem Cell Therapy
Oncolytic Virus Therapy
CGT Drugs Segment by Application
Tumor Disease
Eye Disease
Rare Disease
Others
CGT Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global CGT Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions CGT Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CGT Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze CGT Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGT Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGT Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGT Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the CGT Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CGT Drugs industry.
Chapter 3: Detailed analysis of CGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of CGT Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of CGT Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global CGT Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for CGT Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for CGT Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the CGT Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for CGT Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the CGT Drugs market include Bluebird Bio, Celgene Corporation, Juno Therapeutics, Kite Pharma, Orchard Therapeutics, Spark Therapeutics, Amgen, Fosun Kite Biotechnology and GSK, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for CGT Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of CGT Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for CGT Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CGT Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global CGT Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for CGT Drugs sales, projected growth trends, production technology, application and end-user industry.
CGT Drugs Segment by Company
Bluebird Bio
Celgene Corporation
Juno Therapeutics
Kite Pharma
Orchard Therapeutics
Spark Therapeutics
Amgen
Fosun Kite Biotechnology
GSK
Novartis
SiBiono
Sunway Biotech
Janssen Biotech
Sequoia
CGT Drugs Segment by Type
CAR-T Therapy
Viral Vector Therapy
Stem Cell Therapy
Oncolytic Virus Therapy
CGT Drugs Segment by Application
Tumor Disease
Eye Disease
Rare Disease
Others
CGT Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global CGT Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions CGT Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CGT Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze CGT Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGT Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGT Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGT Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the CGT Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CGT Drugs industry.
Chapter 3: Detailed analysis of CGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of CGT Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of CGT Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
198 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global CGT Drugs Sales Value (2020-2031)
- 1.2.2 Global CGT Drugs Sales Volume (2020-2031)
- 1.2.3 Global CGT Drugs Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 CGT Drugs Market Dynamics
- 2.1 CGT Drugs Industry Trends
- 2.2 CGT Drugs Industry Drivers
- 2.3 CGT Drugs Industry Opportunities and Challenges
- 2.4 CGT Drugs Industry Restraints
- 3 CGT Drugs Market by Company
- 3.1 Global CGT Drugs Company Revenue Ranking in 2024
- 3.2 Global CGT Drugs Revenue by Company (2020-2025)
- 3.3 Global CGT Drugs Sales Volume by Company (2020-2025)
- 3.4 Global CGT Drugs Average Price by Company (2020-2025)
- 3.5 Global CGT Drugs Company Ranking (2023-2025)
- 3.6 Global CGT Drugs Company Manufacturing Base and Headquarters
- 3.7 Global CGT Drugs Company Product Type and Application
- 3.8 Global CGT Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global CGT Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 CGT Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 CGT Drugs Market by Type
- 4.1 CGT Drugs Type Introduction
- 4.1.1 CAR-T Therapy
- 4.1.2 Viral Vector Therapy
- 4.1.3 Stem Cell Therapy
- 4.1.4 Oncolytic Virus Therapy
- 4.2 Global CGT Drugs Sales Volume by Type
- 4.2.1 Global CGT Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global CGT Drugs Sales Volume by Type (2020-2031)
- 4.2.3 Global CGT Drugs Sales Volume Share by Type (2020-2031)
- 4.3 Global CGT Drugs Sales Value by Type
- 4.3.1 Global CGT Drugs Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global CGT Drugs Sales Value by Type (2020-2031)
- 4.3.3 Global CGT Drugs Sales Value Share by Type (2020-2031)
- 5 CGT Drugs Market by Application
- 5.1 CGT Drugs Application Introduction
- 5.1.1 Tumor Disease
- 5.1.2 Eye Disease
- 5.1.3 Rare Disease
- 5.1.4 Others
- 5.2 Global CGT Drugs Sales Volume by Application
- 5.2.1 Global CGT Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global CGT Drugs Sales Volume by Application (2020-2031)
- 5.2.3 Global CGT Drugs Sales Volume Share by Application (2020-2031)
- 5.3 Global CGT Drugs Sales Value by Application
- 5.3.1 Global CGT Drugs Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global CGT Drugs Sales Value by Application (2020-2031)
- 5.3.3 Global CGT Drugs Sales Value Share by Application (2020-2031)
- 6 CGT Drugs Regional Sales and Value Analysis
- 6.1 Global CGT Drugs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global CGT Drugs Sales by Region (2020-2031)
- 6.2.1 Global CGT Drugs Sales by Region: 2020-2025
- 6.2.2 Global CGT Drugs Sales by Region (2026-2031)
- 6.3 Global CGT Drugs Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global CGT Drugs Sales Value by Region (2020-2031)
- 6.4.1 Global CGT Drugs Sales Value by Region: 2020-2025
- 6.4.2 Global CGT Drugs Sales Value by Region (2026-2031)
- 6.5 Global CGT Drugs Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America CGT Drugs Sales Value (2020-2031)
- 6.6.2 North America CGT Drugs Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe CGT Drugs Sales Value (2020-2031)
- 6.7.2 Europe CGT Drugs Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific CGT Drugs Sales Value (2020-2031)
- 6.8.2 Asia-Pacific CGT Drugs Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America CGT Drugs Sales Value (2020-2031)
- 6.9.2 South America CGT Drugs Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa CGT Drugs Sales Value (2020-2031)
- 6.10.2 Middle East & Africa CGT Drugs Sales Value Share by Country, 2024 VS 2031
- 7 CGT Drugs Country-level Sales and Value Analysis
- 7.1 Global CGT Drugs Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global CGT Drugs Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global CGT Drugs Sales by Country (2020-2031)
- 7.3.1 Global CGT Drugs Sales by Country (2020-2025)
- 7.3.2 Global CGT Drugs Sales by Country (2026-2031)
- 7.4 Global CGT Drugs Sales Value by Country (2020-2031)
- 7.4.1 Global CGT Drugs Sales Value by Country (2020-2025)
- 7.4.2 Global CGT Drugs Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.5.2 USA CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.9.2 France CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.16.2 China CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.19.2 India CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt CGT Drugs Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt CGT Drugs Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt CGT Drugs Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Bluebird Bio
- 8.1.1 Bluebird Bio Comapny Information
- 8.1.2 Bluebird Bio Business Overview
- 8.1.3 Bluebird Bio CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Bluebird Bio CGT Drugs Product Portfolio
- 8.1.5 Bluebird Bio Recent Developments
- 8.2 Celgene Corporation
- 8.2.1 Celgene Corporation Comapny Information
- 8.2.2 Celgene Corporation Business Overview
- 8.2.3 Celgene Corporation CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Celgene Corporation CGT Drugs Product Portfolio
- 8.2.5 Celgene Corporation Recent Developments
- 8.3 Juno Therapeutics
- 8.3.1 Juno Therapeutics Comapny Information
- 8.3.2 Juno Therapeutics Business Overview
- 8.3.3 Juno Therapeutics CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Juno Therapeutics CGT Drugs Product Portfolio
- 8.3.5 Juno Therapeutics Recent Developments
- 8.4 Kite Pharma
- 8.4.1 Kite Pharma Comapny Information
- 8.4.2 Kite Pharma Business Overview
- 8.4.3 Kite Pharma CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Kite Pharma CGT Drugs Product Portfolio
- 8.4.5 Kite Pharma Recent Developments
- 8.5 Orchard Therapeutics
- 8.5.1 Orchard Therapeutics Comapny Information
- 8.5.2 Orchard Therapeutics Business Overview
- 8.5.3 Orchard Therapeutics CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Orchard Therapeutics CGT Drugs Product Portfolio
- 8.5.5 Orchard Therapeutics Recent Developments
- 8.6 Spark Therapeutics
- 8.6.1 Spark Therapeutics Comapny Information
- 8.6.2 Spark Therapeutics Business Overview
- 8.6.3 Spark Therapeutics CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Spark Therapeutics CGT Drugs Product Portfolio
- 8.6.5 Spark Therapeutics Recent Developments
- 8.7 Amgen
- 8.7.1 Amgen Comapny Information
- 8.7.2 Amgen Business Overview
- 8.7.3 Amgen CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Amgen CGT Drugs Product Portfolio
- 8.7.5 Amgen Recent Developments
- 8.8 Fosun Kite Biotechnology
- 8.8.1 Fosun Kite Biotechnology Comapny Information
- 8.8.2 Fosun Kite Biotechnology Business Overview
- 8.8.3 Fosun Kite Biotechnology CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Fosun Kite Biotechnology CGT Drugs Product Portfolio
- 8.8.5 Fosun Kite Biotechnology Recent Developments
- 8.9 GSK
- 8.9.1 GSK Comapny Information
- 8.9.2 GSK Business Overview
- 8.9.3 GSK CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.9.4 GSK CGT Drugs Product Portfolio
- 8.9.5 GSK Recent Developments
- 8.10 Novartis
- 8.10.1 Novartis Comapny Information
- 8.10.2 Novartis Business Overview
- 8.10.3 Novartis CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Novartis CGT Drugs Product Portfolio
- 8.10.5 Novartis Recent Developments
- 8.11 SiBiono
- 8.11.1 SiBiono Comapny Information
- 8.11.2 SiBiono Business Overview
- 8.11.3 SiBiono CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.11.4 SiBiono CGT Drugs Product Portfolio
- 8.11.5 SiBiono Recent Developments
- 8.12 Sunway Biotech
- 8.12.1 Sunway Biotech Comapny Information
- 8.12.2 Sunway Biotech Business Overview
- 8.12.3 Sunway Biotech CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Sunway Biotech CGT Drugs Product Portfolio
- 8.12.5 Sunway Biotech Recent Developments
- 8.13 Janssen Biotech
- 8.13.1 Janssen Biotech Comapny Information
- 8.13.2 Janssen Biotech Business Overview
- 8.13.3 Janssen Biotech CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Janssen Biotech CGT Drugs Product Portfolio
- 8.13.5 Janssen Biotech Recent Developments
- 8.14 Sequoia
- 8.14.1 Sequoia Comapny Information
- 8.14.2 Sequoia Business Overview
- 8.14.3 Sequoia CGT Drugs Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Sequoia CGT Drugs Product Portfolio
- 8.14.5 Sequoia Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 CGT Drugs Value Chain Analysis
- 9.1.1 CGT Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 CGT Drugs Sales Mode & Process
- 9.2 CGT Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 CGT Drugs Distributors
- 9.2.3 CGT Drugs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.